Home › Funds › Venrock Adviser, LLC › OCUL

Venrock Adviser, LLC position in OCUL

OCULAR THERAPEUTIX INC · Health Care

Venrock Adviser, LLC reported holding 10,346,926 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q2 2026 13F filing — a position valued at US$101.6M, representing 3.08% of its reported portfolio and ranking #6 among its reported holdings. Venrock Adviser, LLC has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)10.35M sh
Reported value held$101.61M
Portfolio Weight3.08%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Venrock Adviser, LLC's OCUL position evolved

Venrock Adviser, LLC first disclosed a stake in OCUL in Q4 2023 at 7,775,760 shares (US$34.7M). The position peaked in Q3 2025 at 13,161,462 shares, worth US$153.9M. Across 11 filings, Venrock Adviser, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 10,346,926 shares valued at US$101.6M. Notable position changes include a 64% increase in Q1 2024 (shares fell 25% over the following quarter), a 44% trim in Q4 2025 (shares fell 30% over the following quarter), a 41% increase in Q1 2026 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 7.78M $34.68M New
Q1 2024 12.76M $116.14M Add
Q2 2024 12.76M $87.30M Hold
Q3 2024 12.76M $111.03M Hold
Q4 2024 12.76M $108.99M Hold
Q1 2025 12.76M $93.55M Hold
Q2 2025 12.76M $118.44M Hold
Q3 2025 13.16M $153.86M Add
Q4 2025 7.32M $88.81M Reduce
Q1 2026 10.35M $87.64M Add
Q2 2026 10.35M $101.61M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OCUL and 13F data

OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 42 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OCUL

All OCUL fund holders →

FAQ

How long has Venrock Adviser, LLC held OCUL?

Venrock Adviser, LLC has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Venrock Adviser, LLC's current position in OCUL?

As of Q2 2026, Venrock Adviser, LLC holds 10.35M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $101.61M, representing 3.08% of its reported portfolio and ranking #6.

Has Venrock Adviser, LLC been buying or selling OCUL?

In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in OCUL. The position peaked in Q3 2025 at 13.16M shares.

Which other funds hold OCUL?

Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.